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Since its widespread introduction in the early 1980s, immunoglobulin therapy (IG) has been
extensively investigated to understand its mechanism of action and clinical benefits. Research has
also continued to improve its production. The survival benefits of IG for patients with primary
immunodeficiency (PID) are accepted (1). The basic principle of replacing the missing protein has
led to proposals for progressive increases in dosage, delivered intravenously (2), or subcutaneously
(3). It is suggested that continuously increasing IG trough levels decreases pulmonary infections
and damage. In contrast, other studies on large patient cohorts found no correlation between IG
trough level and the incidence of pneumonia and serious infections when trough levels were raised
above 400mg/dl (4, 5). Dosage and other aspects of the therapeutic regimen remain open questions
even in the mainstream indication of substitution therapy in PID. These issues have influenced the
development of product modifications such as highly concentrated solutions and fast infusion rates.
They have also contributed to the increased usage of 16–20% IG infused subcutaneously.
Simple replacement of the antibody defect in PID is now known to be an incomplete explanation
of the mechanism of IG. A range of immunomodulatory and anti-inflammatory mechanisms
are involved (6). These mechanisms are important in the role of IG in autoimmune disorders,
particularly neuropathies including chronic inflammatory demyelinating polyneuropathy (CIDP),
Guillain-Barré syndrome (GBS), and multifocal motor neuropathy (MMN). These indications
represent the largest area of IGuse in the established economies. They contribute greatly to the steady
increase in demand for immunoglobulins experienced in the past 20 years, despite uncertainty in
mechanisms of action. The increase in adverse events, such as thrombogenicity (7) and haemolysis
(8), experienced in recent years makes a better understanding of mechanism and dosage even more
important. The substantial increase in the usage of expensive IG products has also influenced devel-
opments in formulation and infusion practices. Faster infusion of more concentrated solutions will
decrease hospital stay and costs. The subcutaneous route is supposedly easier andmore convenient to
deliver in home therapy settings (9), also potentially decreasing hospital stay. Although approved by
regulatory agencies, these developments have yet to be validated through the long period of clinical
practice experienced with the previous range of IG products.
The increased demand for IG has also seen the rapid development of newmanufacturingmethods
replacing the traditional Cohn fractionation system (10). This system has demonstrated decades of
safety and efficacy and caution is warranted as new methods are introduced into production and
clinical use.
This Research Topic of Frontiers in Immunology has been assembled by an editorial team
which have experienced sufficient “dark forebodings” (11) regarding the uncertainties outlined
above. They have called upon a group of international experts to assess some of these issues from
their perspective. The mechanism of IG on the immune system is explored by Nagelkerke and
Kuijpers (12) who describe the different Fcγ receptors variants on immune cells and the direct IG
effects at the level of the activating Fcγ receptors, including the more recently described FcgRIIc.
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Mitrevski et al. (13) assess analogous mechanisms in the action of
IG in PID, showing that IG at replacement dosages could prime
B cells to an anergic, apoptotic state through the generation of an
increase in CD21low B cells. Matucci et al. (14) discuss the role of
benefits additional to the direct substitution of deficient IG, such
as the immunomodulatory and anti-inflammatory effects of IG
preparations, while Paquin-Proulx and Sandberg (15) discuss the
role of immune activation in the pathology of commonest PID –
common variable immunodeficiency (CVID) – and its alleviation
by IG therapies.
Taken together, this body of work mitigates our “dark forebod-
ings” regarding the lack of clarity on the mechanism of action
of IG. More work is also needed to optimize therapeutic prac-
tice. Kerr et al. (16) note the desirability of progressing beyond
simple, mandated, weight-based dosages in PID, and the need to
approach more individualized therapeutic regimens for different
PID patients. Their approach is augmented by the review of Wolf
et al. (17) demonstrating how the identification of impaired IG
formation may differentiate patients requiring IG from those who
do not. Patient data collected through long term monitoring led
Lucas et al. (18) to conclude that “The goal of replacement therapy
should be to improve clinical outcome and not to reach a particu-
lar IgG trough level” supporting previous work tailoring optimal
IG prophylaxis regimens to clinical and immunological markers
(19). Studies such as those cited should influence treatment pro-
tocols and a negate a “one size fits all” therapeutic approach as
reflected inmany current guidelines. Kerr et al. (16) also note how
little evidence underpins the dosage regimens used in autoim-
mune indications. It is to be wondered that empirically driven
doses developed for the treatment of idiopathic thrombocytopenic
purpura have been extended into the treatment of the various
autoimmune neuropathies. The importance of individualizing
treatment is also discussed by Compagno et al. (20) in their review
of the use of IG in the various acquired hypogammaglobulinemic
diseases. We are aware of large discrepancies between and within
countries in this area, leading to the need for better evidence based
on individualized treatment. Overall, these particular contribu-
tions support the need to improve outcomes in PID as shown by
the study of Tabolli et al. (21) who conclude that Health-Related
Quality of Life in PID patients is not related to IG therapy but to
more sophisticated personal and clinical preferences.
The final component of this Research Topic of Frontiers in
Immunology examines the manufacture of IG therapies and its
effect on the efficacy and safety of the products. Goldacker et al.
(22) show that, despite the mandatory large plasma donation
pool size for IG products, the content of specific, therapeutically
important antibodies is still subject to geographical influence. This
is very important in the context of continuing to ensure that IG
therapies are relevant in the protection of PID patients in different
countries. We suggest that this requires the attention of regulatory
authorities. Finally, Farrugia and Quinti (23) and Späth et al. (24)
discuss the history of the manufacture of IG therapies. They sug-
gest ways whereby changes introduced by companies to optimize
yield andminimize hospital related costsmight alter the repertoire
of specificities and the efficacy of IG. These changesmay also have
played a role in recently observed surges in adverse events. These
observations suggest that amore cautionary approach in the usage
IG therapies is warranted.
Overall, the therapeutics of diseases caused by a deficiency or
an inappropriate type of antibodies continues to be an exciting
and fruitful area of clinical research, and well suited to contribute
to the ongoing evolution in medicine toward more individualized
and patient centric paradigms. We hope that this Research Topic
of Frontiers in Immunology contributes to this debate. Such awide
debate between experts is necessary to enable the new challenges
in immunoglobulin usage.
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